Adam M Veness Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Adam M Veness.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Adam M Veness. Adam M Veness is SVP, General Counsel and Sec. in ACCELERON PHARMA INC ($XLRN) and VP, General Counsel and Sec. in ACCELERON PHARMA INC ($XLRN).
Latest Insider Trading Transactions of Adam M Veness
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 08 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Payment of Exercise | F | 126.69 | 108 | 13,683 | 20,923 | 21 K to 20.9 K (-0.51 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Option Exercise | A | 115.53 | 18,806 | 2,172,657 | 18,806 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Grant | A | 0.00 | 4,868 | 0 | 21,031 | 16.2 K to 21 K (+30.12 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 124.30 | 100 | 12,430 | 16,163 | 16.3 K to 16.2 K (-0.61 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 122.93 | 56 | 6,884 | 16,263 | 16.3 K to 16.3 K (-0.34 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 122.46 | 1,900 | 232,674 | 16,319 | 18.2 K to 16.3 K (-10.43 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Payment of Exercise | F | 124.31 | 942 | 117,100 | 18,219 | 19.2 K to 18.2 K (-4.92 %) |
| Sep 09 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 89.85 | 929 | 83,471 | 19,161 | 20.1 K to 19.2 K (-4.62 %) |
| Sep 09 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 89.20 | 1,071 | 95,533 | 20,090 | 21.2 K to 20.1 K (-5.06 %) |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Option Exercise | M | 27.97 | 6,000 | 167,820 | 0 | |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 87.53 | 417 | 36,500 | 21,161 | 21.6 K to 21.2 K (-1.93 %) |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 86.69 | 1,100 | 95,359 | 21,578 | 22.7 K to 21.6 K (-4.85 %) |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 85.77 | 2,883 | 247,275 | 22,678 | 25.6 K to 22.7 K (-11.28 %) |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 84.62 | 700 | 59,234 | 25,561 | 26.3 K to 25.6 K (-2.67 %) |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 83.49 | 900 | 75,141 | 26,261 | 27.2 K to 26.3 K (-3.31 %) |
| Apr 10 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Buy | M | 27.97 | 6,000 | 167,820 | 27,161 | 21.2 K to 27.2 K (+28.35 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Option Exercise | A | 52.99 | 24,334 | 1,289,459 | 24,334 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Grant | A | 0.00 | 6,369 | 0 | 21,161 | 14.8 K to 21.2 K (+43.06 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 51.23 | 875 | 44,826 | 14,792 | 15.7 K to 14.8 K (-5.58 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 52.83 | 434 | 22,928 | 15,667 | 16.1 K to 15.7 K (-2.70 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 51.23 | 875 | 44,826 | 14,792 | 15.7 K to 14.8 K (-5.58 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 52.83 | 434 | 22,928 | 15,667 | 16.1 K to 15.7 K (-2.70 %) |
| Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 45.75 | 23 | 1,052 | 16,101 | 16.1 K to 16.1 K (-0.14 %) |
| Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 45.18 | 801 | 36,189 | 16,124 | 16.9 K to 16.1 K (-4.73 %) |
| Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 45.75 | 23 | 1,052 | 16,101 | 16.1 K to 16.1 K (-0.14 %) |
| Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 45.18 | 801 | 36,189 | 16,124 | 16.9 K to 16.1 K (-4.73 %) |
| Aug 12 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 45.00 | 3,268 | 147,060 | 16,925 | 20.2 K to 16.9 K (-16.18 %) |
| Jul 17 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 40.71 | 538 | 21,902 | 20,193 | 20.7 K to 20.2 K (-2.60 %) |
| Jun 07 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Option Exercise | A | 40.37 | 6,700 | 270,479 | 6,700 | |
| Jun 07 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Grant | A | 0.00 | 1,100 | 0 | 20,731 | 19.6 K to 20.7 K (+5.60 %) |
| Jun 07 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Option Exercise | A | 40.37 | 6,700 | 270,479 | 6,700 | |
| Jun 07 2019 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Grant | A | 0.00 | 1,100 | 0 | 20,731 | 19.6 K to 20.7 K (+5.60 %) |
Page: 1